Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Gain on bargain purchase (Details)

v3.23.2
Business combinations - Gain on bargain purchase (Details)
3 Months Ended 6 Months Ended
Jun. 01, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
May 31, 2023
$ / shares
Mar. 06, 2023
$ / shares
Merger with TCR2 Therapeutics Inc.          
Gain on bargain purchase   $ 22,155,000 $ 22,155,000    
TCR2 Therapeutics          
Merger with TCR2 Therapeutics Inc.          
Purchase consideration $ (61,620,000)        
Net assets acquired and liabilities assumed 83,775,000        
Gain on bargain purchase $ 22,155,000   22,200,000    
Ratio for issuance of Company's ADSs for each TCR2 stock acquired         1.5117
Closing price of Company's ADS | $ / shares       $ 1.02 $ 1.32
Amount of TCR2's earnings included in the Company's Consolidated Statement of Operations     $ 11,760,000